Prioritize Access to Lifesaving Interventions
During its May meeting in Geneva, the Global Fund Board acknowledged the unprecedented challenges confronting its mission, including financial constraints. In response, and while remaining focused on delivering impact in the fight against HIV, Tuberculosis and Malaria, the Board supported the need to adapt, defer, and reprioritize investments within the current grant cycle. The primary aim of this reprioritization is to preserve the continuity of essential health services and ensure access to life-saving interventions.
The Board mandated that this process should be country-driven, involving meaningful engagement with civil society, communities, ministers of health, implementers, technical partners, and key structures across the Partnership, notably Country Coordinating Mechanisms. Additionally, clear guidance to countries was emphasised, encompassing the criteria for reprioritization, the defined scope of life-saving interventions, and the process and timelines for grant revisions.
Report on the reduced Country Allocation funding for GC7
Through a formulaic approach, initially applying a consistent percentage reduction, and then making qualitative adjustments, all unexecuted country allocations for Grant Cycle 7 were reduced by 11% of their original grant budgets.
In the LAC Region, funding for the top 15 burden countries and regional funding distribution remains mainly unchanged. The Region’s allocation currently stands at 2.9% of the overall GF portfolio, a slight reduction from the original 3%. The Global Fund Secretariat issued a programmatic reprioritization approach and grant revision by mid-June, and countries were informed of specific percentage reductions by June 30th, with a deadline of July 14th for submission of their reprioritised grants. All grants’ revisions will need to be completed and signed by Principal Recipients and the Global Fund Secretariat, with CCMs in agreement, by the end of September.
Due to a large amount of unexecuted funds, Catalytic Multicountry Grants in LAC dedicated to key populations, sustainability, and impact were reduced by approximately $1 million, from the original $6.2 million.
LAC progress towards disease elimination
In June 2025, Suriname received WHO malaria-free certification and became the first Amazonian country to eliminate autochthonous transmission. To sustain this achievement, the Global Fund will continue its support to Suriname’s malaria response through 2027. This continued investment will focus on:
– Preventing reintroduction of the disease;
– Strengthening integrated health systems;
– Building sustainable health financing mechanisms; and
– Boosting regional cooperation for malaria elimination.

Acknowledging that regional solidarity is crucial for sustaining cross-border disease elimination, LAC urged maintaining a balanced geographical distribution in the Sources of Funds. This approach aims to leverage regional initiatives that empower partners to address multi-country challenges and optimize a responsible transition from GF financing, particularly in scenarios of lower replenishment.

Global Fund Secures Access to Lenacapavir for Low- and Middle-Income Countries
The Global Fund announced an agreement with Gilead Sciences to procure lenacapavir, a long-acting injectable for HIV prevention, for low- and middle-income countries (LMICs). This historic agreement ensures LMICs will access an HIV prevention product simultaneously with high-income countries, marking a significant milestone in global health equity. Following the U.S. Food and Drug Administration’s June approval of lenacapavir for HIV prevention, this represents one of the most significant advances in HIV prevention in decades. The ambition is to supply non-profit doses for up to two million people with long-acting PrEP in high-burden countries.

GC8 and Eighth Replenishment
The Global Fund’s Grant Cycle 7 reprioritization and revisions have set the stage for Grant Cycle 8. The Eighth Replenishment, co-hosted by the UK and the Republic of South Africa, is slated for late 2025.
Early signals are promising, with new partners committing resources and traditional donors pledging increased support. Notably, the Children’s Investment Fund Foundation (CIFF) made the first commitment of the eighth replenishment, pledging US$150 million – a five-fold increase. Takeda Pharmaceutical Company also committed JPY 350 million. Additionally, Norway announced a renewed pledge of NOK 2 billion, while Spain pledged €145 million, and Luxembourg committed €13.8 million, both representing increases over their 2022 Seventh Replenishment.

Update on LAC Delegation’s priorities for 2025
The LAC Delegation is focusing on several key areas to enhance its engagement and influence within the Global Fund and the broader LAC region.
Key Priorities

• Diplomatic and Steering Committee Engagement: The delegation continued its dialogue with LAC Diplomatic Missions in Geneva, including an in-person meeting before the 53rd Board Meeting in May. Ongoing collaboration with the LAC Steering Committee provides crucial feedback in preparation for the Global Fund’s Standing Committees and Board Meetings. A recent July 17th Steering Committee meeting highlighted the need for a unified regional approach to procuring Lenacapavir to create synergies and benefit the region.
• Strategic Focus Areas: LAC delegation aims to strengthen its position on new Global Fund Board priorities, specifically Resilient and Sustainable Systems for Health (RSSH) and Climate and Health. The delegation will also develop a narrative to boost communication and engagement with governments and partners across the LAC Region.
• Communication and Collaboration: The delegation continues communication with Haiti’s Fund Portfolio Manager, more recently in the margins of the 53rd Board Meeting. The delegation will leverage its diverse composition to garner support and influence decisions across various levels in LAC, increasing engagement with the Global Fund Secretariat (GFS). Collaboration with other Implementer Constituencies and Member States is being enhanced through pre- and post-board meetings, including a “Regional virtual dialogue on adjustments to GC7 held on May 26th, 2025.”
• Improved Committee Participation: Dr. Massimo Ghidinelli, LAC Alternate Board Member, has been reappointed to the Strategy Committee for a second term (2025-2028), signaling improved LAC representation.
• Showcasing Success and Leadership Transition: The delegation continues to identify and share LAC’s key success stories with the GFS for inclusion in the Eighth Replenishment investment case. Additionally, the nomination process for new LAC Board leadership for the 2025-2027 term is underway. In line with rotation principles, the Latin America Subregion will assume the Board Member role, and the Caribbean Sub-Region will become the Alternate Board Member, with nominations due by Friday, August 12, 2025.

COUNTRY AND REGIONAL COORDINATING MECHANISMS AND OTHER PARTNERS ARE INVITED TO:
– Recognise the contributions of the Global Fund and utilise national, regional and international fora to acknowledge the significant contribution that the Global Fund’s resources have made in preventing new infections and increasing treatment coverage for HIV, TB, and Malaria, and in supporting our efforts in building resilient and sustainable systems for health (RSSH).
– Engage with national governments and partners to develop robust strategies and plans that are essential to protect the gains and sustain the response to the three diseases, while working proactively on transition planning.